Nearly half of all patients who undergo radical prostatectomy for high-risk localized prostate cancer will see their disease return — a failure rate that has persisted for decades despite surgical refinements. PROTEUS, a 2,109-patient Phase 3 trial presented in plenary at ASCO 2026 and simultaneously published in The New England Journal of Medicine, now offers the most credible perioperative data yet to challenge that ceiling: apalutamide plus androgen deprivation therapy, given for six months before and after surgery, reduced the risk of metastasis or death by 20 percent and extended time to subsequent therapy from 41.5 months to 74.2 months.
The pathologic response numbers are striking and deserve direct attention. Only 1.0 percent of patients on hormone therapy alone achieved pathologic complete response or minimal residual disease at the time of surgery. The apalutamide arm reached 8.9 percent — a nearly ninefold difference representing an odds ratio of 10.17. That magnitude of surgical downstaging in prostate cancer is essentially unprecedented in a randomized perioperative trial. It suggests apalutamide is not merely delaying progression downstream but biologically altering the tumor at the time of resection, which carries implications for how pathologic endpoints are weighted in future neoadjuvant designs across the disease.
The design itself deserves scrutiny. Dual primary endpoints — pCR/MRD and metastasis-free survival — were both met with statistical significance, which insulates the trial from the common criticism that pathologic response surrogates don’t translate to clinical benefit. At 61.7 months median follow-up, MFS event rates remain relatively immature, with five-year rates of 78.2 percent versus 73.5 percent. That absolute difference is meaningful to patients but modest in percentage terms, and overall survival data are not yet available. The trial’s credibility rests substantially on the secondary endpoint showing a 29 percent reduction in event-free survival and the dramatic gap in time to subsequent therapy — both directionally consistent and reinforcing.
The single marker to track now is whether the FDA treats pCR/MRD as a sufficient accelerated approval pathway anchor or demands MFS maturity before acting — because that regulatory calculus will determine how quickly perioperative apalutamide reaches patients and whether competitors attempt to replicate this design with next-generation AR inhibitors already approved in later-line disease.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
